Navigation Links
Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress
Date:9/23/2011

s from 20050181.(Abstract 6132) Poster Session on Sunday, Sept. 25, 9:30 a.m. - 12:00 p.m. CEST


  • Study 20050203/PRIME: Effect of Post-Progression Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody (mAb) Therapy in Patients (pts) with Wild-type (WT) KRAS Metastatic Colorectal Cancer (mCRC)(Abstract 6143) Poster Session on Sunday, Sept. 25, 9:30 a.m. - 12:00 p.m. CEST


  • Randomized, Open-label, Phase 3 Study of Panitumumab (pmab) with FOLFOX4 vs FOLFOX4 Alone as 1st-line Treatment for Metastatic Colorectal Cancer (mCRC): the Role of Hypomagnesemia (hypomag) on Efficacy(Abstract 6095) Poster Session on Sunday, Sept. 25, 9:30 a.m. - 12:00 p.m. CESTAbstracts are available on the EMCC website at http://stockholm2011.ecco-org.eu/Programme.aspx. Late breakers and any abstracts that form part of the EMCC media programme will be posted on the day of presentation.

    About XGEVAXGEVA is the first and only RANK Ligand inhibitor approved by the FDA indicated for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. XGEVA was approved following a six month priority review by the FDA. XGEVA is not indicated for the prevention of SREs in patients with multiple myeloma. XGEVA is the first novel bone metastases treatment for advanced cancer patients in nearly a decade. XGEVA is delivered as an every four week 120 mg subcutaneous injection and is not associated with renal toxicity or acute phase reactions.

    XGEVA is a fully human monoclonal antibody that binds to RANK Ligand, a protein essential for the formation, function and survival of osteoclasts (the cells that break down bone). XGEVA prevents RANK Ligand from activating its receptor, RANK, on the surface of osteoclasts, thereby decreasing bone destruction.

    XGEVA has been studied in over 7,000 patients with cancer. In
    '/>"/>


  • SOURCE Amgen
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference
    2. Amgen to Present at the Morgan Stanley Global Healthcare Conference
    3. Amgen to Present at the Baird Healthcare Conference
    4. Amgen to Present at the Stifel Nicolaus Healthcare Conference
    5. Amgen Announces PDUFA Date for XGEVA® Supplemental Biologics License Application
    6. Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion
    7. Amgen Announces Webcast of 2011 Second Quarter Financial Results
    8. Amgen Resolves G-CSF Patent Litigation With Teva
    9. Amgen and UCB Team Up With NASA on Final Space Shuttle Mission to Conduct Preclinical Test of Sclerostin Antibody on Bone Loss
    10. Amgen Announces Modifications to U.S. Prescribing Information for Use of Erythropoiesis-Stimulating Agents in Chronic Kidney Disease
    11. Teachers and Schools Across North America Receive $10,000 Amgen Award for Science Teaching Excellence
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/23/2014)... and MOUNTAIN VIEW, Calif. , July ... leader in translational preclinical research, today unveiled their new ... signaling the transformation of Surpass, corporate culture to one ... our customers. This press release comes on the heels ... were added to the Silicon Valley Team:  David Craig, ...
    (Date:7/23/2014)... 23, 2014 On Tuesday, July 1, ... suit in the 116 th Judicial District ... against RegenLab USA, LLC ("Defendant") for ... Relationships through false and misleading actions, fraud, ... Disparagement through libel, disparagement, defamation, misrepresentation, and ...
    (Date:7/23/2014)... , July 23, 2014 /PRNewswire-iReach/ -- Use of Risk ... programs to delay generic market entry results in $5.4 ... new survey and analysis by economic consulting firm ... - http://photos.prnewswire.com/prnh/20140723/129680 Required by the ... and biologics, REMS programs are intended to improve drug ...
    Breaking Medicine Technology:SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 2SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 3New Analysis Finds $5.4 Billion In Annual Lost Savings From Strategies Geared Toward Delaying Generic Drug Entry 2
    ... Inc ., a clinical-stage epigenetics oncology company, announced today ... with entinostat in combination and as a single agent ... San Antonio Breast Cancer Symposium ... phase 2 study of exemestane with and without entinostat ...
    ... MALVERN, Pa., Dec. 1, 2011 Auxilium Pharmaceuticals, Inc. ... today announced that the first patient has been dosed ... (collagenase clostridium histolyticum) for the treatment of idiopathic ... Shoulder syndrome. (Logo:  http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ...
    Cached Medicine Technology:Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 2Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 3Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 4Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 5Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 2Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 3Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 4Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 5Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 6
    (Date:7/23/2014)... 23, 2014 Global Cardio Care, Inc., ... External Counterpulsation (EECP), is celebrating the 100th birthday ... at the health center. , Weber has been ... receiving ongoing EECP therapy since 1999, he no longer ... CEO of Global Cardio Care, introduced the Sara ...
    (Date:7/23/2014)... FL (PRWEB) July 23, 2014 Bodybuilding.com, ... largest online retailer of nutritional supplements, has officially opened ... BPI SPORTS , the fastest growing sports nutrition ... categories: , Brand of the Year, Best Tasting Protein ... Year, Protein Powder of the year - Whey-HD™, Pre-workout ...
    (Date:7/23/2014)... the secrets to better treating the pernicious disorders of ... a paper from American University,s Center for Behavioral Neuroscience. ... obesity with therapies aimed at areas of the brain ... on the hippocampus could play a role in reducing ... therapies and preventive measures often fall short. This is ...
    (Date:7/23/2014)... PA (PRWEB) July 23, 2014 Four ... have been lauded in the latest ranking of the ... Report . Released online today and slated for ... Guide recognizes Allegheny General Hospital (AGH), Forbes Hospital, Saint ... medical centers across multiple clinical specialties. , ...
    (Date:7/23/2014)... HealthDay Reporter WEDNESDAY, July ... have an additional side benefit -- it may improve ... study. The study found that nearly half of ... prior to the procedure. After surgery, most of those ... said study researcher Dr. Leslee Subak, professor of obstetrics, ...
    Breaking Medicine News(10 mins):Health News:Global Cardio Care Celebrates EECP Patient’s 100th Birthday 2Health News:Vote Now; BPI SPORTS is Nominated for Eight 2014 Bodybuilding.com Supplement Awards 2Health News:Vote Now; BPI SPORTS is Nominated for Eight 2014 Bodybuilding.com Supplement Awards 3Health News:Targeting the brain to treat obesity 2Health News:Targeting the brain to treat obesity 3Health News:Four Allegheny Health Network Hospitals Named High Performers by U.S. News 2Health News:Four Allegheny Health Network Hospitals Named High Performers by U.S. News 3Health News:Weight Loss Surgery May Help Ease Urinary Incontinence 2Health News:Weight Loss Surgery May Help Ease Urinary Incontinence 3
    ... the number of people with vision loss from age-related macular ... is caused by a deterioration of the retina, is the ... of years ago, researchers conducted a large study to see ... beta carotene, along with zinc oxide or zinc alone could ...
    ... surprising finding worried doctors, who say women will now have ... taking a daily aspirin.// ,Pancreatic cancer affects only 31,000 ... within three years. ,The study of 88,000 nurses found ... for 20 years or more had a 58 percent higher ...
    ... who undergo liver transplants have better survival rates than ... reviewed data on more than 48,000 patients who underwent ... 900 of the patients underwent a liver transplant for ... underwent a liver transplant to treat other conditions. ...
    ... the symptoms women experience before having a heart attack ... to experience.// ,Researchers from the University of Arkansas ... attack and were discharged from five different medical sites. ... Researchers asked the women to identify their symptoms before ...
    ... mystery in nearly half of the cases, Some pre-term births ... pressure, bleeding or stretching of the uterus. But in the ... could explain part of the problem. ,Premature birth ... pregnancy -- is a major public health concern because underdeveloped ...
    ... by viral cold are common in preschoolers. These attacks ... by school age. //The current recommendation is that parents ... attack. But whether or not the steroids are effective ... of steroids was no more effective than placebo in ...
    Cached Medicine News:Health News:Aspirin usage linked with pancreatic cancer 2Health News:Women who conceive after a year have a higher chance of giving birth prematurely 2
    Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
    Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
    ... The Shuttle Relay Suture Passer allows braided ... tissue repair procedures. It may be ... suture material and in conjunction with anchors ... anchor) Additionally, the Shuttle Relay can ...
    ... EMR Electronic Medical Record organizes communication ... and with outside practitioners. It also ... and other data that traditionally rely ... the patient chart. With Microsoft Outlook ...
    Medicine Products: